| Gene symbol | RPE65 | Synonyms | BCO3, LCA2, RP20, mRPE65, p63, rd12, sRPE65 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1p31.3 | dbXrefs | |
| Description | retinoid isomerohydrolase RPE65 | ||||
| GTO ID | GTC1930 |
| Trial ID | NCT03597399 |
| Disease | Retinal Dystrophy |
| Altered gene | RPE65 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | voretigene neparvovec|Luxturna |
| Recruitment status | Active, Not Recruiting |
| Title | A Post-Authorization, Multicenter, Longitudinal, Observational Safety Registry Study for Patients Treated With Voretigene Neparvovec in US |
| Year | 2018 |
| Country | United States |
| Company sponsor | Spark Therapeutics, Inc. |
| Other ID(s) | SPKRPE-PASS |
| Vector information | |||||||||||
|
|||||||||||
| Cohort 1 | |||||||||
|
|||||||||